TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure? Correspondence to editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with deco Anja Tiede, Benjamin Maasoumy Clinical and Molecular Hepatology.2025; 31(2): e176. CrossRef
Decreasing systemic inflammation after TIPS: Still hope for the liver: Reply to correspondence on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrh Georg Semmler, Lorenz Balcar, Mattias Mandorfer Clinical and Molecular Hepatology.2025; 31(2): e224. CrossRef
Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation Lucie Simonis, Lorenz Balcar, Anna Schedlbauer, Marta Tonon, Nikolaj Torp, Valeria Santori, Katharina Stopfer, Jan Embacher, Christian Sebesta, Leonie Hafner, Benedikt Silvester Hofer, Nina Dominik, Georg Kramer, Paul Thöne, Michael Trauner, Aleksander Kr Alimentary Pharmacology & Therapeutics.2025; 62(11-12): 1202. CrossRef
Systemic inflammatory indexes as predictors of 18-month mortality among cirrhotic patients receiving transjugular intrahepatic portosystemic shunt Jie Cheng, Xiaobing Wang, Lihua Zhou, Xiaojia Chen, Nuer Tang, Feng Zhou, Feng Ding, Yuan Yang, Jun Lin, Liping Chen Annals of Medicine.2025;[Epub] CrossRef
Nutrition and dietary interventions are a central component in the pathophysiology, but also a cornerstone in the management of patients with non-alcoholic fatty liver disease (NAFLD). Summarizing our rapidly advancing understanding of how our diet influences our metabolism and focusing on specific effects on the liver, we provide a comprehensive overview of dietary concepts to counteract the increasing burden of NAFLD. Specifically, we emphasize the importance of dietary calorie restriction independently of the macronutrient composition together with adherence to a Mediterranean diet low in added fructose and processed meat that seems to exert favorable effects beyond calorie restriction. Also, we discuss intermittent fasting as a type of diet specifically tailored to decrease liver fat content and increase ketogenesis, awaiting future study results in NAFLD. Finally, personalized dietary recommendations could be powerful tools to increase the effectiveness of dietary interventions in patients with NAFLD considering the genetic background and the microbiome, among others.
Citations
Citations to this article as recorded by
Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi Journal of Advanced Research.2026; 80: 893. CrossRef
Ultrafiltered mulberry leaf glutelin mitigates non-alcoholic fatty liver disease through modulation of lipid metabolism, inflammation, and serum metabolomics Mingxi Li, Hongyan Li, Jia Zou, Renqin Li, Haoqi Zhang, Wenhan Yang, Xiyang Wu, Chongzhen Sun Food & Function.2026; 17(2): 819. CrossRef
Long-Term Fructose Intake Induces Moderate Liver Inflammation but Does not Overlap with the Detrimental Effects of the Ketogenic Diet on Hepatic Steatosis in Rats Júlia Galbiati de Souza, Glaucivan Gomes Gurgel, Fernanda Marques Rodrigues, Ribanna Aparecida Marques Braga, Rosana Aparecida Manólio Soares, Luís Alberto de Pádua Covas Lage, Iberê Cauduro Soares, Débora Levy, Nágila Raquel Teixeira Damasceno Inflammation.2026;[Epub] CrossRef
Effects of Intermittent Calorie Restriction in Nondiabetic Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Han Ah Lee, Hyeyoung Moon, Yuri Kim, Jeong Kyong Lee, Hye Ah Lee, Hwi Young Kim Clinical Gastroenterology and Hepatology.2025; 23(1): 114. CrossRef
Total choline intake, liver fibrosis and the progression of metabolic dysfunction-associated steatotic liver disease: Results from 2017 to 2020 NHANES Siraphat Taesuwan, Matina Kouvari, Andrew J. McKune, Demosthenes B. Panagiotakos, Julaluk Khemacheewakul, Noppol Leksawasdi, Pornchai Rachtanapun, Nenad Naumovski Maturitas.2025; 191: 108150. CrossRef
Treating Metabolic Dysregulation and Senescence by Caloric Restriction: Killing Two Birds with One Stone? Lara Russo, Serena Babboni, Maria Grazia Andreassi, Jalil Daher, Paola Canale, Serena Del Turco, Giuseppina Basta Antioxidants.2025; 14(1): 99. CrossRef
Monascus pilosus SWM-008 red mold rice and its components, monascinol and monascin, reduce obesity in a high-fat diet-induced rat model through synergistic modulation of gut microbiota and anti-lipogenesis Chin-Feng Liu, Hui-Tzu Chuang, Chia-Shu Wang, Ya-Wen Hsu, Tzu-Ming Pan, Chun-Lin Lee Food & Function.2025; 16(3): 966. CrossRef
Dietary and lifestyle indices for hyperinsulinemia and odds of MAFLD in overweight and obese children and adolescents Ali Nikparast, Maryam Razavi, Parmis Mirzaei, Pooneh Dehghan, Mahdi Amani Farani, Golaleh Asghari Scientific Reports.2025;[Epub] CrossRef
YouTube as a Source of Information for Dietary Guidance and Advisory Content in the Management of Non-Alcoholic Fatty Liver Disease Kagan Tur Healthcare.2025; 13(4): 351. CrossRef
Sex-Specific Biochemical and Histopathological Effects of Chronic Meat-Based vs. Plant-Based Burger Consumption in a Rodent Model Cristina Filip, Ruxandra Ștefănescu, Bianca-Eugenia Ősz, Amalia Pușcaș, Corneliu Tanase, Adela Nechifor-Boilă, Amelia Tero-Vescan Foods.2025; 14(5): 888. CrossRef
Non-alcoholic fatty liver disease: diet therapy and pharmacotherapy M. L. Maksimov, V. A. Dudareva, V. O. Vovk, V. I. Sklyarova, S. O. Ivashchenko, A. A. Shikaleva Terapevt (General Physician).2025; (3): 37. CrossRef
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers” Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen Clinical and Molecular Hepatology.2025; 31(2): e186. CrossRef
An umbrella review of the association between dietary factors and hepatocellular carcinoma risk Han Li, Qi-Hang Cao, Hui Liu, Lun-Jie Yan, Zi-Niu Ding, Han-Chao Wang, Rui Dong, Bao-Wen Tian, Cheng-Long Han, Zhao-Ru Dong, Long-Shan Yang, Xin-Cheng Mao, Yu-Chuan Yan, Dong-Xu Wang, Tao Li Food & Function.2025; 16(10): 3879. CrossRef
ASS1 is a hub gene and possible therapeutic target for regulating metabolic dysfunction-associated steatotic liver disease modulated by a carbohydrate-restricted diet Shaojun Chen, Yanhua Bi, Lihua Zhang Molecular Diversity.2025; 29(4): 3717. CrossRef
2,5-Dihydroxybenzoic Acid Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Targeting the CCL2-CCR2 Axis to Reduce Lipid Accumulation Chien-Yun Hsiang, Kuang-Ting Hsu, Hsin-Yi Lo, Yun-Jhu Hou, Tin-Yun Ho Nutrients.2025; 17(11): 1835. CrossRef
Food Nutrients and Bioactive Compounds for Managing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review Erdenetsogt Dungubat, Kohei Fujikura, Masahiko Kuroda, Toshio Fukusato, Yoshihisa Takahashi Nutrients.2025; 17(13): 2211. CrossRef
Amaranthus graecizans L. Mitigates Hyperlipidemia-Induced Nonalcoholic Fatty Liver Disease in Experimental Rats: Future Pharmaceuticals Nadiah S. Alzahrani, Bayan Aljahdali, Aeshah Alhosain, Abeer Abdullah Alasmari, Touseef Amna, Soha Mohamed Yousef Pharmaceuticals.2025; 18(8): 1196. CrossRef
Higher Food Inflammation Index Is Linearly Associated With Higher Risk of MASLD: A Cross‐Sectional Study Based on the NHANES (1999–2020) Qingwan Yang, Xin Cai, Zhenghua Xiao Food Science & Nutrition.2025;[Epub] CrossRef
Comparative efficacy of different diet modalities on metabolic profiles and liver functions in metabolic dysfunction-associated fatty liver disease: a network meta-analysis Jiahui Zou, Fei Tian, Shuqing Cui, Jing Hou, Zhenhua Li, Yaochen Wei, Haozhe Cui, Yunpeng Li, Shuanghao Zhou, Zechao He, Xiangming Ma BMC Gastroenterology.2025;[Epub] CrossRef
Ramadan fasting model exerts hepatoprotective, anti-obesity, and anti-hyperlipidemic effects in an experimentally-induced nonalcoholic fatty liver in rats Abeer A. Alasmari, Abdulrahman S. Al-Khalifah, Ahmed S. BaHammam, Noura M. S. Alshiban, Ahmad T. Almnaizel, Hesham S. Alodah, Maha H. Alhussain Saudi Journal of Gastroenterology.2024; 30(1): 53. CrossRef
Decrease in Leptin Expression in the Liver after Prolonged Every-Other-Day Feeding in C57Bl/6 Male Mice Katarzyna Piotrowska, Maciej Tarnowski, Patrycja Tomasiak, Michał Czerewaty, Katarzyna Zgutka, Andrzej Pawlik Physiologia.2024; 4(1): 100. CrossRef
Beneficial effects of intermittent fasting on nonalcoholic fatty liver disease: a narrative review Qingxuan Deng, Ruyue Lv, Haoqi Zou, Tangbin Zou Egyptian Liver Journal.2024;[Epub] CrossRef
Synergistic Effects of Fructose and Food Preservatives on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): From Gut Microbiome Alterations to Hepatic Gene Expression Tomas Hrncir, Eva Trckova, Lucia Hrncirova Nutrients.2024; 16(21): 3722. CrossRef
The Interplay Between Depression, Probiotics, Diet, Immunometabolic Health, the Gut, and the Liver—A Secondary Analysis of the Pro-Demet Randomized Clinical Trial Oliwia Gawlik-Kotelnicka, Jakub Rogalski, Karolina H. Czarnecka-Chrebelska, Jacek Burzyński, Paulina Jakubowska, Anna Skowrońska, Dominik Strzelecki Nutrients.2024; 16(23): 4024. CrossRef
Prevalence of Liver Steatosis Among Workers in Ouagadougou and Associated Factors: A Cross‐Sectional Study Delphine Napon‐Zongo, Jeoffray Diendere, Armel M. Sanou, Abou Coulibaly, Abdoulaye Dera, Nina G. M. Ouattara, Augustin N. Zeba, Seni Kouanda JGH Open.2024;[Epub] CrossRef
Dietary modulation of gut microbiota affects susceptibility to drug-induced liver injury Han Pan, Delei Song, Zhiyi Wang, Xin Yang, Pei Luo, Wei Li, Yan Li, Mengxue Gong, Chenhong Zhang Gut Microbes.2024;[Epub] CrossRef
Non-alcoholic fatty liver disease in people with normal body weight S. V. Turkina, I. A. Tyshchenko, M. N. Titarenko Experimental and Clinical Gastroenterology.2024; (10): 36. CrossRef
Optimal choice of diet and food for NAFLD G. V. Shavkuta, L. B. Lazebnik Experimental and Clinical Gastroenterology.2024; (10): 98. CrossRef
Effect of Nut Consumption on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis Ling Pan, Jing Sui, Ying Xu, Qun Zhao Nutrients.2023; 15(10): 2394. CrossRef
Synergistic Effect of Diet and Physical Activity on a NAFLD Cohort: Metabolomics Profile and Clinical Variable Evaluation Francesco Maria Calabrese, Giuseppe Celano, Caterina Bonfiglio, Angelo Campanella, Isabella Franco, Alessandro Annunziato, Gianluigi Giannelli, Alberto Ruben Osella, Maria De Angelis Nutrients.2023; 15(11): 2457. CrossRef
Diet and non-alcoholic fatty liver disease, a short narrative review W.J. Kwanten Acta Gastro Enterologica Belgica.2023; 86(2): 306. CrossRef
β-hydroxybutyrate: A crucial therapeutic target for diverse liver diseases Ke Li, Wen-hong Wang, Jia-bin Wu, Wei-hua Xiao Biomedicine & Pharmacotherapy.2023; 165: 115191. CrossRef
Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease” Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 1050. CrossRef
Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro-Narro Expert Review of Gastroenterology & Hepatology.2025; 19(7): 755. CrossRef
Combination of modified albumin-bilirubin grade and platelet count to predict high-risk varices in patients with hepatocellular carcinoma Prooksa Ananchuensook, Kingkomon Piyawannasuth, Sirinporn Suksawatamnuay, Panarat Thaimai, Nipaporn Siripon, Supachaya Sriphoosanaphan, Kessarin Thanapirom, Piyawat Komolmit, Wenyu Lin PLOS One.2025; 20(7): e0327967. CrossRef
Noninvasive model based on liver and spleen stiffness for predicting clinical decompensation in patients with cirrhosis Long-Bao Yang, Xin Gao, Meng Xu, Yong Li, Lei Dong, Xin-Di Huang, Xiao She, Dan-Yang Zhang, Qian-Wen Zhang, Chen-Yu Liu, Shu-Ting Fan, Yan Wang World Journal of Gastroenterology.2025;[Epub] CrossRef
Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension Georg Semmler, Lukas Hartl, Yuly Paulin Mendoza, Benedikt Simbrunner, Mathias Jachs, Lorenz Balcar, Michael Schwarz, Benedikt Silvester Hofer, Laurenz Fritz, Anna Schedlbauer, Katharina Stopfer, Daniela Neumayer, Jurij Maurer, Robin Szymanski, Elias Lauri Hepatology.2024; 80(4): 887. CrossRef
Portal hypertension and its prognostic implications in patients with Wilson's disease Lukas Burghart, Peter Ferenci, Oleksandr Petrenko, Mattias Mandorfer, Michael Schwarz, Michael Gschwantler, Michael Trauner, Thomas Reiberger, Albert Friedrich Stättermayer Alimentary Pharmacology & Therapeutics.2024; 60(2): 257. CrossRef
Folic acid supplementation is associated with a decreased mortality and reduced hospital readmission in patients with decompensated alcohol-related liver cirrhosis Laura Buttler, Anja Tiede, Marie Griemsmann, Hannah Rieland, Jim Mauz, Julia Kahlhöfer, Heiner Wedemeyer, Markus Cornberg, Tammo L. Tergast, Benjamin Maasoumy, Katharina L. Hupa-Breier Clinical Nutrition.2024; 43(8): 1719. CrossRef
Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients” Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani Clinical and Molecular Hepatology.2023; 29(1): 188. CrossRef
Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase” Jeong-Ju Yoo, Sang Gyune Kim Clinical and Molecular Hepatology.2023; 29(2): 513. CrossRef
Validation of non‐invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Seung Woon Paik, Dong Hyun Sinn Liver International.2023; 43(9): 1966. CrossRef
Lymphatic drainage dysfunction is related to clinically significant portal hypertension Ruixue Ma, Yasuko Iwakiri Hepatology International.2023; 17(6): 1327. CrossRef
First
Prev
